Drugs / MVA EBNA1/LMP2 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01094405 | Mar 2010 → Aug 2020 | Epstein-Barr virus infection, nasopharyngeal carcinoma | Chinese University of Hong Kong | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA EBNA1/LMP2 vaccine | “The purpose of this study is to evaluate the efficacy (clinical benefit rate) of MVA EBNA1/LMP2 vaccine in patients with persistent, recurrent or metastatic nasopharyngeal...” NCT01094405 ↗ |
| Modality | Vaccine | “MVA EBNA1/LMP2 vaccine” NCT01094405 ↗ |